Migraine is a neurological disorder that affects approximately 1 in 6 Americans and leads to over 1 million emergency department visits in the US annually. Just like many neurological conditions, the treatment landscape of triptans, opioids and NSAIDs has fallen short of providing a sustainable solution for migraine patients with drugs that have subpar efficacy and intolerable side-effects. The condition has been difficult to study and characterize due to varying levels of severity, causes and symptoms and traditional therapies have not specifically addressed the disease pathology of migraines

3 Patient Engagement Technology Myths

A recent survey by Boston Consulting Group, exploring what patients want from pharma companies and how well companies are meeting those needs, revealed a deficiency in patient engagement. The growing demand for improved and more efficient communication between patients and healthcare entities has created an opportunity for pharmaceutical manufacturers to promote patient engagement through digital tools. However, three common myths may be holding them back

6 Healthcare Trends Impacting Pharma Commercialization

What commercialization strategies should life sciences companies focus on as they look ahead. It’s crucial to monitor trends closely to navigate the evolving healthcare landscape better and build winning strategies. Here are the top six healthcare trends affecting pharma commercialization today: 1

Is Your Life Science Company Taking Full Advantage of Digital Technology?

The pharmaceutical industry generates immense volumes of data, so it would make sense that pharma companies are ahead of the curve by leveraging the latest technologies to transform their operations across the value chain. However, historically, the pharmaceutical sector has been slow to embrace digital technologies. In a highly regulated, high-risk environment, it is no surprise that pharma companies tend to be risk averse

Is Your Pharma Product at Risk for a Mid-Life Cycle Crisis?

Commercial launch is an expensive and risky endeavor, especially for small life science companies. According to a recent report, about half of all the drugs launched in the last fifteen years underperformed market expectations by more than 20%. In fact, over half failed to reach $250 million in peak U.S